Sector pending / Biological Products, Except Diagnostic SubstancesUpdated 2026-05-10 22:07 UTC

FRA/PMRA stock hub

FRA/PMRA has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FRA/PMRAis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.7B

Frankfurt Stock Exchange

Market data

Price

Recent price action with selectable time range.

FRA/PMRAFRA/PMRA

—

Loading chart…

In the news

Latest news · FRA/PMRA

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E22.6

P25 n/aP50 n/aP75 n/a

Trailing P/E21.5

P25 n/aP50 n/aP75 n/a

ROE36

P25 n/aP50 n/aP75 n/a

ROIC48.9

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FRA/PMRA market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

204

Groups with data

Currency

EUR

Showing 204 of 204 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Spain
Country code	DE
Employees	505
Employees Change	-9%
Employees Change Percent	-1.77
Enterprise value	EUR 1.6B
Exchange	Frankfurt Stock Exchange
Financial currency	EUR
First seen	2026-05-10
Industry	Biological Products, Except Diagnostic Substances
Last refreshed	2026-05-10
Market cap	EUR 1.7B
Price	EUR 102
Price currency	EUR
Rev Per Employee	446,398.02x
Sic	2836
Symbol	fra/PMRA
Website	https://www.pharmamar.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	4.66%
EV Earnings	19.97x
EV/EBIT	24.95x
EV/EBITDA	22.26x
EV/FCF	26.48x
EV/Sales	7.13x
FCF yield	3.51%
Forward P/E	22.61x
P/B ratio	6.92x
P/E ratio	21.47x
P/S ratio	7.66x
PE Ratio3 Y	237.2x
PE Ratio5 Y	144.96x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	28.58%
EBITDA Margin	31.17%
FCF margin	26.92%
Gross margin	94.45%
Gross Profit	EUR 212.9M
Gross Profit Growth	28.32%
Gross Profit Growth Q	10.67%
Gross Profit Growth3 Y	8.84%
Gross Profit Growth5 Y	0.84%
Net Income	EUR 80.5M
Net Income Growth	304.85%
Net Income Growth3 Y	40.86%
Net Income Growth5 Y	-2.4%
Pretax Margin	28.9%
Profit Margin	35.7%
Profit Per Employee	EUR 159,343
ROA	11.2
Roa5y	6.83
ROCE	21.76
ROE	35.99
Roe5y	27.39
ROIC	48.92

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	12.45%
Cagr1y	37.29%
Cagr3y	42.07%
Cagr5y	5.61%
Div CAGR3	14.96%
Div CAGR5	10.48%
FCF Growth5 Y	-11.64%
OCF Growth5 Y	-10.28%
Revenue Growth	28.27x
Revenue Growth Q	10.4x
Revenue Growth3 Y	8.37x
Revenue Growth5 Y	0.33x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 0.63
Assets	EUR 385.3M
Cash	EUR 167.9M
Current Assets	EUR 273.5M
Current Liabilities	EUR 89.2M
Debt	EUR 47.5M
Debt EBITDA	EUR 0.66
Debt Equity	EUR 0.19
Debt FCF	EUR 0.78
Equity	EUR 249.7M
Interest Coverage	39.28
Liabilities	EUR 135.6M
Long Term Assets	EUR 111.8M
Long Term Liabilities	EUR 46.4M
Net Cash	EUR 120.3M
Net Cash By Market Cap	EUR 6.97
Net Cash Growth	35.33%
Net Debt EBITDA	EUR -1.71
Net Debt Equity	EUR -0.48
Net Debt FCF	EUR -1.98
Tangible Book Value	EUR 245.9M
Tangible Book Value Per Share	EUR 14.16

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	3.06
Inventory Turnover	0.24
Net Working Capital	EUR 29.4M
Quick ratio	2.33
Working Capital	EUR 184.2M
Working Capital Turnover	EUR 1.32

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Dividend Growth	23.08%
Dividend Growth Years	2%
Dividend per share	EUR 0.8
Dividend Years	6
Dividend Yield	0.85%
Ex Div Date	2025-06-25
Last Dividend	EUR 0.8
Payout Frequency	Annual
Payout Ratio	17.33%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	223.36%
1Y total return	37.26%
200-day SMA	82.02
3Y total return	186.81%
50-day SMA	88.79
50-day SMA vs 200-day SMA	50over200
5Y total return	31.37%
All Time High	144.7
All Time High Change	-29.58%
All Time High Date	2020-10-16
All Time Low	10.96
All Time Low Change	830.08%
All Time Low Date	2018-10-26
ATR	2.27
Ch YTD	35.24
High	101.9
High52	104.2
High52 Date	2026-05-06
High52ch	-2.21%
Low	101.9
Low52	70.6
Low52 Date	2025-11-06
Low52ch	44.33%
Ma50ch	14.77%
Price vs 200-day SMA	24.24%
RSI	63.24
RSI Monthly	67.47
RSI Weekly	70.76
Sharpe ratio	0.96x
Sortino ratio	1.58
Total Return	0.85%
Tr YTD	35.24
Tr1m	15.8%
Tr1w	6.37%
Tr3m	34.7%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR 64.4M
Operating Income Growth	738.6
Operating Income Growth3 Y	46.51
Operating Income Growth5 Y	-9.08
Operating margin	28.58

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	13,425,751%
Net Borrowing	-7,259,000
Shares Insiders	12.04%
Shares Institutions	10.43%
Shares Qo Q	0%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR 60.7M
Average Volume	37.75x
Bv Per Share	14.38
CAPEX	EUR -7.3M
Ch10y	204.7
Ch1m	15.8
Ch1w	6.37
Ch1y	35.87
Ch3m	34.7
Ch3y	175
Ch5y	24.97
Ch6m	41.82
Change	-2.02%
Change From Open	0
Close	104
Days Gap	-2.02
Depreciation Amortization	5,852,000
Earnings Date	2026-04-29
EBIT	EUR 64.4M
EBITDA	EUR 70.3M
EPS	EUR 4.64
F Score	7
FCF	EUR 60.7M
FCF EV Yield	3.78x
Financing CF	-36,735,000
Fiscal Year End	December
Founded	1,986
Graham Number	39.66271
Graham Upside	-61.08
Income Tax	EUR -15.3M
Investing CF	-43,088,000
Is Primary Listing	0
Last Earnings Date	2026-04-29
Last Report Date	2026-03-31
Last Split Date	2020-07-22
Last Split Type	Reverse
Lynch Fair Value	EUR 23.73
Lynch Upside	-76.71
Ma150	81.5
Ma150ch	25.04%
Ma20	96.54
Ma20ch	5.55%
Net CF	-11,427,000
Next Earnings Date	2026-07-27
Open	101.9
P FCF Ratio	28.46
P OCF Ratio	25.4
Payment Date	2025-06-27
Ppne	59,657,000
Price Date	2026-05-08
Price EBITDA	EUR 24.58
Ptbv Ratio	7.03
Relative Volume	4.26x
Revenue	225,431,000x
Tax By Revenue	-6.79x
Tr6m	41.82%
Z Score	8.74

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

FRA/PMRA dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+0.8%

$0.80 annual per share

Payout ratio

+17.3%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+10.5%

2 consecutive years of growth

Total shareholder yield

+0.8%

Next ex-dividend date: 2025-06-25

Performance

FRA/PMRA stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FRA/PMRA?

Insider, institutional, and short-interest positioning.

Institutional ownership

+10.4%

Share of float held by funds and institutions

Insider ownership

+12.0%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

n/a

Negative means the company is buying back shares.

Technical

FRA/PMRA momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

63.2

Neutral momentum band

Price vs 200-day MA

+24.2%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

0.96

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FRA/PMRA

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/PMRA stock rating?

fra/PMRA is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/PMRA analysis?

The full report lives at /stocks/fra/PMRA/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/PMRA?

The latest report frames fra/PMRA around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/PMRA page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.